Here are the 10-K annual reports from Exascale Labs Holdings Inc. (XLAB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow XLAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XLAB filings page.
Exascale Labs Holdings Inc. reported that predecessor Exascale Labs Inc. generated $14,822,799 in fiscal 2026 revenue, versus $7,015,512 in fiscal 2025. Gross profit was $2,418,253 versus $1,105,197; net loss widened to $12,162,391 from $7,659,667, and operating cash used rose to $2,754,624 from $1,010,799.
The Business Combination closed August 27, 2026. Former Legacy Exascale holders received 19,354,261 Class A and 30,645,739 Class B shares as $500.0 million of merger consideration, based on a deemed $10.00 per share. All outstanding SAFEs converted into Class A shares at closing; SAFE liabilities were approximately $29.1 million at June 30, 2026. The company obtained access to approximately $11.8 million in retained cash proceeds.
At June 30, 2026, cash and cash equivalents were $2,693,586, USDC was $2,160,746, and current liabilities were $31,885,500. Those conditions raised substantial doubt about Legacy Exascale’s ability to continue as a going concern. After considering the combination, SAFE conversion, cash proceeds and forecast, management concluded the doubt was alleviated and expected sufficient liquidity for at least 12 months after the financial statements were issued.